Investor Relations

We are a team of passionate entrepreneurs reinventing drug development
hero image hero image
Investor Relations
We are a team of passionate entrepreneurs reinventing drug development

Company Overview

Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Stock Snapshot

NASDAQ GS: RAIN Rain Oncology (Common Stock)

Learn More